CASE REPORT

Symptomatic bladder metastasis of malignant melanoma: a case report

Rahoui Moez¹,*, Mrad Daly Khaireddine¹, Wajih Sahnoun¹, Alia Zehani², Mokhtar Bibi¹, Yassine Ouannes¹, Ahmed Sellami¹, Sami Ben Rhouma¹, Yassine Nouira¹

¹Department of Urology, Hopital La Rabta, Tunis, Tunisia ²Department of Pathology, Hopital La Rabta, Tunis, Tunisia

*Correspondence address. Department of Urology, Hospital La Rabta, La Rabta Jebbari, Tunis 1007, Tunisia. Tel: +21-6-28-12-14-24; Fax : (216) (71) 570 506; E-mail: rmoez099@gmail.com

Abstract

Bladder metastasis of cutaneous malignant melanoma is an extremely rare condition, with less than 10 cases reported in the last 30 years in the English literature. Bladder localization is most often asymptomatic, explaining the frequency of cases discovered during autopsy in multi-metastatic patients. We report a case of symptomatic malignant melanoma metastasis to the bladder in a 31-year-old patient.

INTRODUCTION

Bladder metastasis of malignant melanoma is a rare clinical entity, with less than 10 cases reported in the last 30 years in the English literature. Bladder localization is most often asymptomatic explaining the frequency of cases discovered during autopsy. We report a case of symptomatic malignant melanoma metastasis to the bladder in a 31-year-old patient.

CASE REPORT

A 31-year-old man presented with asthenia, intermittent total hematuria and low urinary tract signs. This patient had been diagnosed 3 years ago with malignant melanoma in the right inguinal area and had undergone wide local excision and right inguinal node dissection. He had been treated 6 months ago with Dacarbazine-based chemotherapy for a lymph node recurrence. His Hematuria was first explored by abdominal ultrasound, showing an irregular wall thickening in the right lateral face and the floor of the bladder measuring 5 × 3 cm (Fig. 1) with a vascularized appearance (Color Dop and a right hydronephrosis. Computed tomography (CT) scan confirmed ultrasound findings and showed metastatic lymph nodes in both inguinal areas and in internal iliac and latero-aortic areas measuring up to 3 cm and a 4 cm mass in the left adrenal gland (Fig. 2). Digital rectal examination finds a fixed bladder floor. He underwent cystoscopy, which revealed a huge solid non-papillary black pigmented lesion located in the floor and in the right lateral face of the bladder hiding the right ureteral meatus (Fig. 3). Monopolar loop electrocautery was used to excise the tumor as a palliative treatment to stop hematuria. Tumor shavings were particularly blackish (Fig. 4). Pathological examination confirmed the diagnosis of malignant melanoma (Figs 5 and 6). The
The patient was actually treated with chemotherapy for a metastatic malignant melanoma. Although an evaluation CT scan showed significant progression under chemotherapy of the majority of lymph nodes, our patient is no longer complaining of hematuria or low urinary tract signs.

**DISCUSSION**

Malignant melanoma is a common cancer and extremely aggressive. The genitourinary tract and adrenal gland is a common site of metastasis from malignant melanoma. Most of the metastasis from malignant melanoma is asymptomatic [1]. Bladder metastasis is rarely symptomatic, although approximately 15% of the cases are symptomatic, with hematuria being the most common presentation [2]. The definitive modality for diagnosis was cystoscopy, which demonstrated frequently pigmented and nodular or vegetating lesions in the bladder wall, which was confirmed on biopsy and careful histopathologic evaluation. Adrenal metastases are most often clinically and biochemically silent. CT represents the reference method for diagnosis of adrenal melanoma metastasis [3]. Metastatic malignant melanoma cells usually exhibit variable expression of the common melanoma-associated antigen. In cases where the clinical history of primary melanoma is noted, the diagnosis of bladder metastases is often straightforward and can be confirmed by immunohistochemically stains. In some instances, this variability can create a diagnostic dilemma in which case-special immunostaining is useful. These include antibodies to the gp100, Melan-A/MART-1 or other melanoma antigens [1, 4]. Treatment of patients with systemic melanoma should include careful evaluation for the potential role of different treatments like surgery, radiotherapy and chemotherapy [5]. Transurethral resection of the bladder tumor used for diagnostic
purposes could improve the urinary system symptoms. Surgery can be offered to patients with a single metastasis. The use of chemotherapy in the treatment of metastatic melanomas is for palliative purposes. It has not shown efficacy in improving survival [6]. Immunotherapy can be effective in the treatment of metastatic melanoma. Numerous immunotherapy strategies including melanoma vaccines, interferon-alpha and interleukin-2 [IL-2] have been used in the treatment [7]. The prognosis for metastatic malignant melanomas is very poor. Despite the use of new therapeutic modalities, the survival rate of metastatic malignant melanoma patients has not changed considerably over the past three decades. The overall median survival of patients with systemic metastasis from malignant melanoma is about 6–7.5 months, with an estimated 5-year survival rate of 6% [8].

CONCLUSION

Melanoma of the bladder has been very rarely reported. It is typically a secondary recurrence in patients with widespread metastatic melanoma originating from the skin. A detailed patient history and careful examination of the skin are necessary to determine the primary or metastatic nature of the tumor.

REFERENCES

1. Lee CS, Komenaka IK, Hurst-Wicker KS, Deraffele G, Mitcham J, Kaufman HL. Management of metastatic malignant melanoma of the bladder. Urology 2003;62:351.
2. Rajaratnam A, Waugh J. Adrenal metastases of malignant melanoma: characteristic computed tomography appearances. Australas Radiol 2005;49:325–9.
3. Menendez Lopez V, Alvarez-Vijande Garcia R, Sole Arques M, Carretero Gonzalez P. Bladder metastasis of malignant melanoma: report of a case. Arch Esp Urol 2002;55:1277–9.
4. Efesoy O, Cayan S. Bladder metastasis of malignant melanoma: a case report and review of literature. Med Oncol 2011;28:S667–9.
5. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull. 1995;51:609–30.
6. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;1:75–81.
7. Acquavella N, Kluger H, John R, Leonard F, Harold T, Stephan A, et al. Toxicity and activity of a twice daily highdose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569–76.
8. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;18:193–201.